CellGenix® rh SCF
GMP and Preclinical grade
CellGenix Recombinant Human SCF reliably supports survival and differentiation of hematopoietic stem cells (HSCs) and progenitor cells as well as the differentiation of cord blood-derived CD34+ cells into natural killer cells (NK cells). It is also used to differentiate embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into megakaryocytes and T cells. CellGenix rh SCF is produced in our dedicated animal-free facility ensuring maximum safety for optimal use in ATMP manufacturing.
Stem Cell Factor (SCF) is a cytokine that is produced by fibroblasts and endothelial cells. It plays an important role in hematopoiesis, spermatogenesis and melanogenesis.
SCF is used in the cell and gene therapy space for the expansion of HSCs that are used for transplantation.
CellGenix GMP Recombinant Human SCF is produced following all applicable GMP guidelines and allows for the safe use in accordance with USP Chapter <1043>, Ph. Eur. General Chapter 5.2.12 and ISO Technical Standard 20399.
Our GMP cytokines are provided with documented evidence of purity, potency, consistency and stability. In combination with our expert regulatory and technical support this will help simplify your raw material qualification and validation efforts.
CellGenix® Recombinant Human Stem Cell Factor
CellGenix® GMP rh SCF
CellGenix® Preclinical rh SCF
CellGenix® rh SCF
- Produced in our dedicated animal-free facility
- Compliant to USP Chapter <1043> and Ph. Eur. General Chapter 5.2.12 (GMP)
- FDA Drug Master File available (GMP)
GMP & Preclinical Grade
- Seamless transition from preclinical development to ATMP manufacturing
- Expansion of HSCs in combination with CellGenix GMP SCGM Medium
- Differentiation of cord blood-derived CD34+ cells into NK cells
- Differentiation of ESCs and iPSCs into megakaryocytes and T cells
Highest GMP Quality Standard
- High lot-to-lot consistency – save time and costs on revalidations
- Performance reliability – rely on consistent product performance
- Highest purity – ensure the safety of your ATMP
- Extremely low endotoxin levels – improve safety and reproducibility
- Expert regulatory & technical support – rely on experience
Read more about our GMP Quality
Safe │ GMP Compliant │ Reliable
Expressed in E. coli
Human SCF, accession # P21583, Glu26-Ala189
Lyophilized from a 0.2 µm-filtered solution containing 25 mM sodium phosphate, 150 mM sodium chloride and 1 mM EDTA, pH 7.4
Both product grades are produced under the same conditions in a GMP facility, ensuring an equal product quality and performance. We offer a more comprehensive QC testing including tighter specifications and documentation for our GMP products: Preclinical vs GMP.
|Molecular weight||19.4 kDa||19.4 kDa|
|Purity||≥ 95% as determined by SDS-PAGE||≥ 97% as determined by SDS-PAGE|
|Activity||≥ 0.5 x 106 IU/mg, calibrated against NIBSC #91/682 Measured in a cell proliferation assay using a SCF-dependent cell line, TF-1||0.5 – 2 x 106 IU/mg, calibrated against NIBSC #91/682 Measured in a cell proliferation assay using a SCF-dependent cell line, TF-1|
Batch specific activity on CoA
|Endotoxin level||< 1000 EU/mg||≤ 50 EU/mg|
|Intended use||Intended for preclinical ex vivo use. Not intended for therapeutic use.||Intended for clinical ex vivo use. Not intended for human in vivo application.|
Recommended in sterile water to a final concentration of 250 µg/ml for 50 µg vials or 500 µg/ml for 1 mg vials.
Ambient temperature. Please refer to Technote
to learn more about our shipment validation procedure.
Storage & Stability
Store lyophilized cytokine at -20°C to -80°C.
Store a 250 µg/ml reconstituted cytokine solution:
• 4 weeks at 2°C to 8°C under sterile conditions after reconstitution. Store in the original container.
• 4 months at -20°C to -80°C under sterile conditions after reconstitution. Store in 60 µl aliquots in polypropylene cryogenic vials.
Avoid repeated freeze/thaw cycles.
CellGenix GMP rh SCF has an activity of 0.5 – 2 × 106 IU/mg
The activity of GMP rh SCF was measured in a cell proliferation assay using the SCF-dependent cell line TF-1. It was calibrated against the NIBSC #91/682.
You can find the batch specific activity on the certificate of analysis (CoA).
We offer the following to assist you with your regulatory approval process:
- Comprehensive documentation (e.g. DMFs, Regulatory Support Files, Certificates of Origin)
- Outstanding QC support (e.g. extensive stability data)
- The possibility to audit our production site
- Detailed batch specific test results on our Certificates of Analysis
- Change notifications prior to relevant changes
Customized solutions can be provided to meet special compliance needs. Contact our Regulatory Support Team for all your regulatory requests & questions:
Phone: +49 761 88 88 9-302
In order to stay up-to-date and help improve regulatory guidance we are actively involved in many of the regulatory initiatives and discussions. We were amongst others actively involved in the discussions for the setup of Ph. Eur. General Chapter 5.2.12 and the ISO Technical Standard 20399.
- Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, AA. et al., 2018, The New England Journal of Medicine
- Gene therapy in a patient with Sickle Cell disease
Ribeil, JA. et al., 2017, The New England Journal of Medicine
- In vivo Efficacy of umbilical Cord Blood Stem Cell-Derived NK Cells in the treatment of Metastatic Colorectal Cancer
Veluchamy, JP. et al., 2017, Frontiers in Immunology
- Large scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming
Moreau, T. et al., 2016, Nature communications
- A critical role of CXCR2 PDZ-mediated interactions in endothelial progenitor cell homing and angiogenesis
Hou, Y. et al., 2015, Stem Cell Research & Therapy
- Phenotypic, Morphological and Adhesive Differences of Human Hematopoietic Progenitor Cells Cultured on Murine versus Human Mesenchymal Stromal Cells
Reichert, D. et al., 2015, Scientific reports
- 3′, 4′-Dimethoxyflavone and valproic acid promotes the proliferation of human hematopoietic stem cells.
Kaur, K. et al., 2013, Stem Cell Research & Therapy
- A Short-activating RNA Oligonucleotide Targeting the Islet β-cell Transcriptional Factor MafA in CD34+ Cells
Reebye, V. et al., 2013, Molecular Therapy: Nucleic Acids
- MRI tracking of FePro labeled fresh and cryopreserved long term in vitro expanded human cord blood AC133+ endothelial progenitor cells in rat glioma
Janic, B. et al., 2012, PLoS One
- Is Anticancer Vaccine Possible: Experimental Application of Produced mRNA Transfected Dendritic Cells Derived from Enriched CD34+ Blood Progenitor Cells
Lazarova, P. et al., 2012, Immunodeficiency, Chapter 3
- Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
Spanholtz, J. et al., 2011, PloS One
- Polarization and migration of hematopoietic stem and progenitor cells rely on the RhoA/ROCK I pathway and an active reorganization of the microtubule network
Fonseca, AV. et al., 2010, The journal of biological chemistry
- Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution
Delaney, C. et al., 2010, Nature Medicine